gptkbp:instanceOf
|
gptkb:virus
|
gptkbp:Baltimore_classification
|
Group IV (+)ssRNA viruses
|
gptkbp:biosafetyLevel
|
BSL-2 (attenuated), BSL-3 (wild type)
|
gptkbp:caps
|
gptkb:VP1
gptkb:VP2
gptkb:VP3
gptkb:VP4
|
gptkbp:cause
|
gptkb:Poliomyelitis
|
gptkbp:containsSerotype
|
Type 1
Type 2
Type 3
|
gptkbp:decommissioned
|
gptkb:Heat
gptkb:Formalin
Chlorine
|
gptkbp:discoveredBy
|
gptkb:Karl_Landsteiner
gptkb:Erwin_Popper
|
gptkbp:discoveredIn
|
1908
|
gptkbp:enveloped
|
No
|
gptkbp:eradicationEffort
|
Global Polio Eradication Initiative
|
gptkbp:family
|
gptkb:Picornaviridae
|
gptkbp:firstOralVaccineDevelopedBy
|
gptkb:Albert_Sabin
|
gptkbp:firstVaccineDevelopedBy
|
gptkb:Jonas_Salk
|
gptkbp:genomeSense
|
Positive-sense
|
gptkbp:genomeType
|
Single-stranded RNA
|
gptkbp:genus
|
gptkb:virus
|
gptkbp:hostedBy
|
gptkb:Humans
|
https://www.w3.org/2000/01/rdf-schema#label
|
Poliovirus
|
gptkbp:incubationPeriod
|
7-14 days
|
gptkbp:infectiousPeriod
|
7-10 days before and after onset of symptoms
|
gptkbp:notableContributor
|
First virus to be synthesized in vitro
Used in molecular biology research
|
gptkbp:notableFeature
|
No animal reservoir
High mutation rate
|
gptkbp:notableLaboratoryStrain
|
gptkb:Mahoney_strain
|
gptkbp:notableOutbreaks
|
gptkb:20th_century_polio_epidemics
|
gptkbp:notableResearchYear
|
2002
|
gptkbp:order
|
gptkb:Picornavirales
|
gptkbp:recipient
|
gptkb:CD155_(PVR)
|
gptkbp:replicationSite
|
gptkb:Cytoplasm
|
gptkbp:species
|
gptkb:Enterovirus_C
|
gptkbp:structure
|
Icosahedral
|
gptkbp:symptom
|
Fever
Fatigue
Headache
Vomiting
Paralysis
Neck stiffness
Pain in limbs
|
gptkbp:transmissionRoute
|
Fecal-oral
Oral-oral
|
gptkbp:vaccineAvailable
|
Yes
|
gptkbp:vaccineType
|
gptkb:Inactivated_poliovirus_vaccine
gptkb:Oral_poliovirus_vaccine
|
gptkbp:WHOStatus
|
Type 1 still endemic in some countries
Type 2 eradicated (2015)
Type 3 eradicated (2019)
|
gptkbp:bfsParent
|
gptkb:virus
|
gptkbp:bfsLayer
|
5
|